These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10872100)

  • 1. Dissolution of omeprazole from delayed-release solid oral dosage forms.
    Farinha A; Bica A; Martins JM; Pais JP
    Drug Dev Ind Pharm; 2000 Jul; 26(7):785-90. PubMed ID: 10872100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of capsules containing omeprazole in enteric coated pellets.
    Palummo M; Cingolani A; Dall L; Volonté MG
    Boll Chim Farm; 2000; 139(3):124-8. PubMed ID: 10961022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.
    Storpirtis S; Rodrigues D
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1101-7. PubMed ID: 9876567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 5. Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole.
    He W; Fan LF; Du Q; Xiang B; Li CL; Bai M; Chang YZ; Cao DY
    Chem Pharm Bull (Tokyo); 2009 Feb; 57(2):122-8. PubMed ID: 19182399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
    Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
    Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric-coated formulations.
    Liu W; He X; Li Z; Gao X; Ma Y; Xun M; Liu C
    Pharm Res; 2013 Feb; 30(2):596-605. PubMed ID: 23135820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration].
    Navarro MA; Raei N; Torres F; Granero L; García-Zaragoza E; Esplugues JV; Esteban Peris J
    Gastroenterol Hepatol; 1998 Feb; 21(2):63-70. PubMed ID: 9549180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form.
    Ronchi F; Sereno A; Paide M; Sacré P; Guillaume G; Stéphenne V; Goole J; Amighi K
    Int J Pharm; 2019 Aug; 567():118416. PubMed ID: 31175991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt.
    El-Sayed A; Boraie NA; Ismail FA; El-Khordagui LK; Khalil SA
    East Mediterr Health J; 2007; 13(6):1427-37. PubMed ID: 18341192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an oral formulation of omeprazole.
    Pilbrant A; Cederberg C
    Scand J Gastroenterol Suppl; 1985; 108():113-20. PubMed ID: 3858973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole--a new formulation.
    Armstrong D
    Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro study on capsule formulations of omeprazole containing enteric coated granules.
    Pandey VP; Phanindrudu A; Manavalan R; Livingston J
    Boll Chim Farm; 2002; 141(6):419-22. PubMed ID: 12577509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of orally administered enteric-coated omeprazole on gastric acid secretion in horses.
    Andrews FM; Doherty TJ; Blackford JT; Nadeau JA; Saxton AM
    Am J Vet Res; 1999 Aug; 60(8):929-31. PubMed ID: 10451198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence evaluation of two omeprazole enteric-coated formulations in humans.
    Farinha A; Bica A; Pais JP; Toscano MC; Tavares P
    Eur J Pharm Sci; 1999 Mar; 7(4):311-5. PubMed ID: 9971914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
    Shimizu T; Kameoka N; Iki H; Tabata T; Hamaguchi N; Igari Y
    Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1029-35. PubMed ID: 12951443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.
    Yang R; Lin Y; Chen K; Huang J; Yang S; Yao A; Yang X; Lei D; Xiao J; Yang G; Pei Q
    AAPS J; 2024 Jul; 26(4):82. PubMed ID: 38997548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.